Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Mapping the Targets of Antimalarial Compounds Through Chemical Profiling. (MALARIA TARGETS ID)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Life-long training and career development
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: United Kingdom
Call:  (FP7-PEOPLE-2013-CIG, 2013)
Start date: 2014-09-01
End date: 2018-08-31
Duration (months): 48.0
Total project cost (EUR): 100000.0
EU funding (EUR): 100000.0
Participants: 2
Project status: CLOSED

Malaria is one of the most devastating infectious diseases affecting half of the world population and killing close to a million people every year. Widespread resistance of the malaria parasite to most front-line drugs and the rapid emergence of resistance against new therapies have made the validation of novel pharmaceutical targets and the identification of potent pharmacophores extremely urgent. In an effort to synergize basic research with malarial drug development the pharmaceutical industry has run large phenotypic screens and identified thousands of new compounds with antimalarial activity. These hits represent a treasure-throve of chemical tools to study parasite biology. However, in order to harness the potential benefits of these hits it is crucial to determine the mechanism of action by which these compounds exert their antiparasitic activities. Here we propose a global chemical proteomic approach to identify the molecular targets of some of these bioactive molecules using broad-spectrum activity-based probes (ABPs). ABPs are small reporter molecules that use the conserved catalytic or binding mechanism of an enzyme family to covalently modify their active sites. A tag embedded within the structure of the probe allows for visualization of labeled proteins in a gel-based format. When used in a complex proteome, ABPs report on the active site occupancy of all members of an enzyme family, thus making them ideal tools to simultaneously screen dozens of targets against potential inhibitors. The goal of this proposal is to run a pilot study by screening 400 of the most promising antimalarial compounds against all serine hydrolases, cysteine proteases, and ATPases found in infected red blood cells. We will then use the latest advances in Plasmodium genetics to validate the identified enzymes as new antimalarial targets. Importantly, the methodology outlined in this proposal is broadly applicable to any biological system and expandable to other enzyme families.

Keywords: parasitology,chemical biology,malaria,high throughput screening,phenotypic screen,drug development,target identification,proteases
Logarithmically Correlated Fields and their Applications (LCFA)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Life-long training and career development
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: Israel
Call:  (FP7-PEOPLE-2013-CIG, 2013)
Start date: 2014-03-01
End date: 2018-02-28
Duration (months): 48.0
Total project cost (EUR): 100000.0
EU funding (EUR): 100000.0
Participants: 1
Project status: CLOSED

We propose to continue the study of the extremal structure of logarithmically correlated random fields, such as the (discrete or continuous) Gaussian free field and the positions of particles in a branching random walk or branching Brownian motion. Such study includes finding the complete asymptotics of the extremal process of the 2D discrete GFF (based on work started in Biskup-Louidor (2013)), studying properties of the limit and extending these results to other log-correlated fields. This will the first time extremal asymptotics are derived for log-correlated fields. Based on these, we then propose to study exponentials of log-correlated fields, such as the ones appearing in the Gaussian multiplicative chaos, the Liouville quantum gravity measure and the logarithmic random energy model, at least at sub-critical temperatures, thereby resolving several conjectures about their existence, asymptotics and properties. Finally, using the above, we wish to study the Glauber dynamics for the log random energy model, or more generally the motion of a particle in a log-correlated potential, in and out-of equilibrium and at least at sub-critical temperatures. Results as in the (non-logarithmic) random energy model, such as converges to a K-process and the fractional kinetics process are expected at first order, necessitating more subtle observables.

Keywords: gaussian free field,branching random walk,branching brownian motion,harmonic crystal,extreme values,spin glass,random walk in random environment,glauber dynamics,cox process,poisson-dirichlet
GMP Two Year Safety Testing (G-TWYST)

Framework: FP7 — Cooperation
Programme: Food, Agriculture and Fisheries, and Biotechnology
Destination: Life sciences, biotechnology and biochemistry for sustainable non-food products and processes
Action type: Collaborative project
Countries involved: Germany,Spain,Netherlands,Germany,Slovakia,Austria,Netherlands,United Kingdom
Call:  (FP7-KBBE-2013-FEEDTRIALS, 2013)
Start date: 2014-04-21
End date: 2018-04-20
Duration (months): 48.0
Total project cost (EUR): 3773113.0
EU funding (EUR): 2999890.0
Participants: 9
Project status: CLOSED

G-TwYST will execute rat feeding trials with GM maize NK 603 based on OECD Test Guidelines and according to EFSA considerations. In the case of maize NK603 two 90-day and a combined 2-year chronic toxicity/carcinogenicity study will be performed. By combining the results of the G-TwYST project with those of the GRACE project (90-day and 1-year study with maize MON810) it will be possible for the first time to describe the potential medium term and long term toxic effects of the two above-mentioned events. Partners will strictly comply with international standards and norms concerning feeding trials and closely collaborate with EFSA. Feeding stuff used in the trials will be produced according to the principles of good agricultural practice. The project will analyse and report the results of the feeding trials and develop recommendations on the scientific justification and added value of long-term feeding trials for GMO risk assessment. The project will ensure scientific excellence, independence and transparency of both the research process and the results. Transparency and accessibility of project plans and results is a key characteristic of the project and will be ensured by establishing a project website and by using an open access database set up by GRACE as information hubs. Results will be published as open access journal papers. Dedicated engagement, communication, and dissemination activities will target scientists, policy makers and a broad range of stakeholders. Participatory steps will be included in the planning as well as in the interpretation/conclusion phase. Moreover, the views of risk assessment and regulatory bodies as well as wider societal issues will also be taken into consideration. The results of the project will enable risk managers drawing conclusions with regard to framework of the currently applicable GM food/feed risk assessment requirements and procedures in the EU.

Keywords: nk603 maize,mon810 maize,2-year feeding study,90-day feeding study,combined chronic toxicity/carcinogenicity study,risk assessment,gmp,gmo,genetically modified plants,stakeholder
Novel antibiotics against multi-drug resistant pathogens (PATRES)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Proof of concept grants
Action type: Support for frontier research (ERC)
Countries involved: Israel
Call:  (ERC-2013-PoC, 2013)
Start date: 2014-05-01
End date: 2015-04-30
Duration (months): 12.0
Total project cost (EUR): 163876.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

Being among the most significant challenges facing modern medicine, the massive growth of multi-drug resistance prolongs illnesses and increases the risk of early death, thus creating a global clinical threat. The limited arsenal of available antibiotics dictates an urgent need for novel approaches, as it suffers from (i) resistance to one or several antibiotics and (ii) marginal distinction between the antibiotics sites in bacteria and in patients, causing toxicity or side effects. As resistance-acquiring mechanisms are species-specific and as many antibiotics target ribosomes, we developed novel methodologies for increasing the battery of available potent antibiotics by benefiting from the breakthroughs of our NOVRIB ERC funded project: the unexpected rapid determination of the only available high resolution structure of a ribosome from a genuine pathogen, worldwide. In this PoC project we propose to exploit the unique tools provided by this structure for the commercialization of newly discovered binding sites and contact-networks, for suggesting novel synthetic antibiotics and/or for structure-based alterations of existing ones. Thus, we identified chemical elements associated solely with pathogenic specificity that can provide valuable clues for designing modifications that should increase the potency of the currently known antibiotics; alongside proposing novel binding sites on the ribosome surface. The advantages of our approach are (1) less chance of fast developing resistance, (2) reduced toxicity, (3) potential of decelerating multi-drug antimicrobial resistance development, (4) improved existing ribosomal antibiotics. The significance of our innovating approach stems also from the potential market and the compelling socioeconomic benefits. Hence, we are currently approaching the stage of commercialization and public dissemination.

Keywords: 322581
CopyMe3D: High-Resolution 3D Copying and Printing of Objects (COPYME3D)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Proof of concept grants
Action type: Support for frontier research (ERC)
Countries involved: Germany
Call:  (ERC-2013-PoC, 2013)
Start date: 2014-09-01
End date: 2015-08-31
Duration (months): 12.0
Total project cost (EUR): 166357.2
EU funding (EUR): 149960.0
Participants: 1
Project status: CLOSED

With recent advances in 3D scanning and 3D printing we are at the advent of low-cost and easy-to-use 3D copying machines. While scanning objects is feasible today, existing commercial systems are either slow or rely on expensive equipment, require skilled users, and will often generate incomplete 3D geometry. The algorithms developed in the ERC project ConvexVision provide the foundations for easily scanning people and objects with minimal effort for direct printing of colored 3D models. This opens novel markets such as plastic surgery planning or 3D photography. Currently, the size of the industry for 3D printing equipment and services is estimated at around 2.4 billion Euro with an annual growth of 30% over the past five years. Assuming that in five years only one in a thousand photos is a 3D print, we will soon have an annual market of 2.5 million printed 3D objects. Therefore, this is the right time to bring this technology to market. The aim of the proposed PoC project CopyMe3D is to develop software which creates high-resolution 3D models of people or objects from an RGB-D camera such as Microsoft Kinect. The goal is to develop an easy-to-use software that generates a printable, colored 3D model of the scanned object. In March 2013, Dr. Jürgen Sturm and the ERC Principal Investigator Prof. Daniel Cremers founded the university spin-off company FabliTec UG which offers a basic software tool for 3D scanning. While this first step into the market was successful, the support of the PoC project CopyMe3D will enable us to substantially advance this effort on three levels: Firstly, we will bring in convex super-resolution techniques developed in the ERC project ConvexVision to drastically increase the resolution of scanned 3D models. Secondly, we will integrate user feedback making the software more intuitive and easy to use. And thirdly, we will conduct a systematic market analysis in order to identify relevant market segments for 3D scanning technology.

Keywords: 240168
The control of ice nucleation (IceControl) (ICECONTROL)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Proof of concept grants
Action type: Support for frontier research (ERC)
Countries involved: United Kingdom
Call:  (ERC-2013-PoC, 2013)
Start date: 2014-06-01
End date: 2015-05-31
Duration (months): 12.0
Total project cost (EUR): 158564.8
EU funding (EUR): 142632.0
Participants: 1
Project status: CLOSED

The control of ice nucleation is key to improving the efficacy of a wide range of industrial processes, but effective methods of controlling ice nucleation have been remarkably elusive. In many manufacturing processes, from cryo-storage of stem cells for regenerative medicine, making ice cream or even freeze concentration of alcoholic beverages, the aqueous medium will supercool well below its equilibrium melting point before freezing. Controlling this nucleation processes is critical, for example, in the cryopreservation of cells excessive supercooling usually results in their death. Hence, there is a demand for materials which catalyse ice formation and are compatible with a range of industrial processes. In my ERC Starting grant we made a major new discovery concerning an important class of ice nucleating particles for clouds in the Earth's atmosphere (Atkinson et al., Nature, 2013). We showed that a minor component of many desert soils, feldspars, are very effective ice nucleants; this was surprising since it was previously thought that the clay minerals were the most efficient. This new knowledge offers a new route to controlling ice nucleation in many applications. The initial focus will be on a range of applications in cryopreservation since it is these applications I am well positioned to exploit, but also represent a significant high value and growing market. Many other opportunities exist and during the course of IceControl we will explore the feasibility of the application of this technology in areas such as freeze drying and ice cream production. The specific tasks in IceControl will be optimising delivery of feldspar, manufacture of feldspar, assessing regulatory issues, trials and testing, dissemination of results, technical marketing, assessment of significant markets and the formation of a business plan.

Keywords: 240449
Giant Organic Magnetoresistance BioSensing (GOMBS)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Proof of concept grants
Action type: Support for frontier research (ERC)
Countries involved: Netherlands
Call:  (ERC-2013-PoC, 2013)
Start date: 2014-10-01
End date: 2015-09-30
Duration (months): 12.0
Total project cost (EUR): 149999.54
EU funding (EUR): 149999.54
Participants: 1
Project status: CLOSED

The GOMBS project prepares the commercialization of ultrasensitive point-of-care biosensors for early-stage detection of life-threatening diseases, based on the largest MR effect ever observed at room temperature and small magnetic fields, recently discovered by the PI [Science 341, 257 (2013)]. Target biomolecules are specifically attached to the sensor and magnetic nanoparticle (NP) labels, and electrically detected using this huge MR effect (patent in preparation). We will develop sensors for disease markers such as prostate-specific antigen (prostate cancer), troponin (heart muscle damage) and hypermethylated DNA (several cancers). The PI will make use of his long-standing, fruitful collaborations with organic chemists on magnetic NP synthesis and assembly, and functional organic monolayers. As the most competitive advantages of our sensor technology we identify (1) high selectivity, sensitivity and speed (2) very simple, scalable device concept, (3) robustness against environmental fluctuations (e.g. temperature-, pH-independent), (4) small size (allowing implementation in a bioassay device for multiple target molecules), and (5) low cost price. Recognizing commercial potential and a clear market need, the GOMBS team is highly motivated to start up a new venture for exploitation of the proposed biosensor. We will develop the optimal business strategy with an experienced business executive. We will collect market insights for calculating the feasibility, and for setting up a strategic mode of action. In collaboration with a patent attorney a strategy will be defined that secures IP protection. GOMBS will deliver a technical proof of concept and a comprehensive business plan including presentation of the product and concept, the team, business and IP strategy, business model, market size and dynamics, technical and operational planning, a SWOT analysis, investment need, and financial forecasts. This plan will form the basis for the launch of a spin-off company.

Keywords: 240433
Commercialisation of a robotic platform enabling high-precision force control in multi-dimensional applications (ROBOMED)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Proof of concept grants
Action type: Support for frontier research (ERC)
Countries involved: Switzerland
Call:  (ERC-2013-PoC, 2013)
Start date: 2014-06-01
End date: 2015-05-31
Duration (months): 12.0
Total project cost (EUR): 163669.0
EU funding (EUR): 149757.0
Participants: 1
Project status: CLOSED

Current robotic technologies show severe limitations in multi-dimensional applications requiring force control, both from the accuracy and safety perspective. Although combined hardware and control concepts have been developed that enable accurate force control in a single degree of freedom, the majority of tasks necessitates superior force control capabilities in multiple degrees of freedom. Within our ERC grant, we have developed a robotic platform that enables high-precision force control in multi-dimensional applications. This system meets the requirements for safe and high-fidelity body-weight supported gait training of rodents. Our system consists of exchangeable and adaptable elastic force sensing modules that can be attached to state-of-the-art macrostructure robots and enable, combined with specific control laws, highly accurate force control along 4 independent degrees of freedom. The interface consists of a compact entity that is relatively light and can be produced at low costs. Within the ERC PoC ‘Robomed’ the goal is to develop a proposition package for potential investors. On the technical side we will create a novel prototype to validate our robotic technology, which will result in a technical report. In consultation with regulatory specialists a roadmap will be developed to obtain regulatory approval based on the norms and procedures for robotics. A patent protects our robot-assisted training and additional patentability of our findings is currently evaluated. A strategy to overcome any obstacles identified is developed. Market opportunities for our technology include translational research, restoring fine locomotor and manual tasks in humans and industrial applications. These market segments will be extensively analysed and subsequently prioritised within the commercialisation strategy. Results will be assembled in a detailed business plan that is presented to several venture capitalists, existing robotic companies and other relevant stakeholders.

Keywords: 261247
Breakthrough Laminar Aircraft Model wind tunnel testing in Europe (BLAME)

Framework: FP7 — Cooperation
Programme: Joint Technology Initiatives (Annex IV-SP1)
Theme: Public-private partnerships
Destination: Clean Sky
Action type: Article 171 of the Treaty
Partnership: CLEAN-SKY (Art-185)
Countries involved: Netherlands
Call:  (SP1-JTI-CS-2013-02, 2013)
Start date: 2013-12-16
End date: 2014-06-15
Duration (months): 6.0
Total project cost (EUR): 988756.0
EU funding (EUR): 741567.0
Participants: 1
Project status: CLOSED

Natural laminar flow wings will be flight tested, within a project called BLADE. A new outer laminar wing will be fitted on the legacy A340-300 wing. A large scale, low speed wind tunnel test in the DNW-LLF (Large Low speed Facility) is offered aiming at generating high quality data allowing flight clearance for the BLADE Flight Test Demonstrator providing know how for performing representative test for future laminar wings. Wind tunnel results will complement results from CFD, especially in ground effect and stall conditions Furthermore testing will allow assessment of basic longitudinal & lateral handling qualities characteristics of the large scale wind tunnel model. The DNW test environment for the wind tunnel model supplied by Airbus features: • A test section size (8 m width and 6 m height), perfectly fitted to the subject wind tunnel model to limit model buoyancy and wall effects • Dorsal sting set-up • Wind speed range (0 – 100 m/s, corresponding to appr. 0.3 Mach number and a Reynolds number of upto 3*106) • Excellent flow quality (very low turbulence level, below 0.1%, which is critical for laminar flow testing) • Innovative ground effect simulation (by means of a moving belt system, capable of running at 80 m/s) • High end data acquisition systems capable of acquiring (un)steady sensor data from model load balances (forces), pressure tabs, Kulites etc. • Flexible data processing systems to convert the acquired data conform Airbus TARDIS (Transnational Aerodynamic Results Data Information System) specification for further analysis purposes. • And last but not least excellent staff, with 35 years of experience in industrial wind tunnel testing as part of aircraft development programs.

Keywords: wind tunnel testing laminar flow ground effect stall